OJOG  Vol.3 No.4 , June 2013
A controlled, randomized, open label study in postmenopausal women to assess the safety and the efficacy of a vaginal moisturizer: An instrumental approach
Abstract: Background: Vulvovaginal atrophy is an inflammatory condition linked with estrogenic deficiency, as well as decreased lubrication. The study aimed at the objective measurements of vaginal moisture (RH%), in fertile women and in postmenopausal women before and during treatment with a non-estrogenic moisturizing gel. Methods: The study followed a stepwise design. Acute: 5 women with postmenopausal vaginal dryness were measured their RH% at baseline and 30 minutes after the application of a moisturizer. Fertile Controls: 20 women were measured in the follicular phase and20 inthe luteal phase. Chronic: Forty postmenopausal women with mild/moderate vaginal dryness were randomly assigned to treatment (once/day for the first week and twice/week for the following 11 weeks) or untreated control group. Primary parameter was RH%, done by means of a vaginal hygrometer manufactured and validated for the specific purpose. Secondary parameters were the evaluation of erythema and oedema, scored for severity. Results: Fertile women showed an average 93/95 RH%, independently on the cycle phase. Postmenopausal women had 49/69 RH% in absence of any treatment. A 37% increased RH% was observed 30 min after a single application. During chronic treatment, RH% measured not earlier than 2 hours after the application of the product, resulted 7.8% to 10.4% higher than baseline (p < 0.05). Erythema improved accordingly. Conclusions: The vaginal moisturizer proved to be safe and to increase vaginal moisture short after treatment initiation; moreover, its effect proved to be long lasting.
Cite this paper: Sparavigna, A. , Tenconi, B. , Ponti, I. , Bulgheroni, A. and Scarci, F. (2013) A controlled, randomized, open label study in postmenopausal women to assess the safety and the efficacy of a vaginal moisturizer: An instrumental approach. Open Journal of Obstetrics and Gynecology, 3, 395-399. doi: 10.4236/ojog.2013.34073.

[1]   Santos, I. and Clissold, S. (2010) Urogenital disorders associated with oestrogen deficiency: The role of promestriene as topical oestrogen therapy. Gynecological Endocrinology, 26, 644-651. doi:10.3109/09513591003767948

[2]   Bachmann, G.A. and Nevadunsky, N.S. (2000) Diagnosis and treatment of atrophic vaginitis. American Family Physician, 61, 3090-3096.

[3]   Palacios, S. (2009) Managing urogenital atrophy. Mauritas, 63, 315-318. doi:10.1016/ turitas.2009.04.009

[4]   Mac Bride, M.B., Rhodes, D.J. and Shuster, L.T. (2010) Vulvovaginal atrophy. Mayo Clinic Proceedings, 85, 87-94. doi:10.4065/mcp.2009.0413

[5]   Goldstein, I. (2010) Recognizing and treating urogenital atrophy in postmenopausal women. Journal of Women’s Health, 19, 425-432. doi:10.1089/jwh.2009.1384

[6]   Costantino, D. and Guaraldi, C. (2008) Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: An open, non-controlled clinical trial. European Review for Medical and Pharmacological Sciences, 12, 411-416.

[7]   Morali, G., Polatti, F., Metelitsa, E.N., Mascarucci, P., Magnani, P. and Brunenghi Marrè, G. (2006) Open, noncontrolled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittel Forschung—Drug Research, 56, 230-238.

[8]   Lewis, V. (2009) Undertreatment of menopausal symptoms and novel options for comprehensive management. Current Medical Research and Opinion, 25, 2689-2698.

[9]   Nachtigall, L.E. (1994) Comparative study: Replens versus local estrogen in menopausal women. Fertility and Sterility, 61, 178-180.